GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Total Stockholders Equity

AbbVie (AbbVie) Total Stockholders Equity

: $10,360 Mil (As of Dec. 2023)
View and export this data going back to 2012. Start your Free Trial

AbbVie's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $10,360 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. AbbVie's Book Value per Share for the quarter that ended in Dec. 2023 was $5.87. The ratio of a company's debt over equity can be used to measure how leveraged this company is. AbbVie's Debt-to-Equity for the quarter that ended in Dec. 2023 was 5.73.

AbbVie Total Stockholders Equity Historical Data

The historical data trend for AbbVie's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,172.00 13,076.00 15,408.00 17,254.00 10,360.00

AbbVie Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Stockholders Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17,254.00 13,274.00 12,866.00 12,094.00 10,360.00

AbbVie  (NYSE:ABBV) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

AbbVie's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(10360-0)/1765.94
=5.87

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

AbbVie's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(7191 + 52194) / 10360
=5.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of AbbVie's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (AbbVie) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Total Stockholders Equity
Comparable Companies
MRK PFE JNJ AMGN BMY GILD BIIB OGN SCLX AMRN LLY XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4568 TSE:4519 XTER:BAYN SHSE:600276
Traded in Other Exchanges
ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB0:Germany 4AB:Germany 4AB:Germany 4AB:Germany ABBV:Canada ABBV34:Brazil ABBV:Austria
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
Website
http://www.abbvieinvestor.com
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Executives
Nicholas Donoghoe officer: SVP, Enterprise Innovation 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin director 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis director 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez officer: Chairman of the Board and CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg officer: Sr. V.P., U.S. Commercial Ops. 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis officer: EVP, GC and Secretary 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart officer: SVP, US Commercial Operations 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee officer: SVP, Controller 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents officer: SVP, Chief Financial Officer 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt officer: SVP, Operations 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom officer: SVP & Pres Global Allerg Aesth 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin director 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond officer: EVP, Chief HR Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino officer: EVP, R&D and CSO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch officer: Chief Strategy Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092